Language selection

Government of Canada / Gouvernement du Canada

Search

ARCHIVED - Guidelines for the Prevention and Control of Mumps Outbreaks in Canada

We have archived this page and will not be updating it.

You can use it for research or reference.

We have archived this page and will not be updating it.

You can use it for research or reference.

 

References

  1. National Advisory Committee on Immunization. Canadian immunization guide. 7th ed. Ottawa: Public Health Agency of Canada, 2006.
  2. Bell A, Fyfe M, Bigham M et al. Outbreak of mumps among young adults – Vancouver, British Columbia. CCDR 1997;23(22):169-72.
  3. Bruneau A, Duchesne C. Outbreak of mumps, Montreal, October 1998 to March 1999 – with a particular focus on a school. CCDR 2000;26(8):69-71.
  4. Alberta Health and Wellness. Public health notifiable disease management guidelines (June 2005). http://www.health.gov.ab.ca/ professionals/NotifiableDiseases.html. Date of access: November 23, 2007.
  5. Watson-Creed G, Saunders A, Scott J et al. Two successive outbreaks of mumps in Nova Scotia among vaccinated adolescents and young adults. CMAJ 2006;175(5):483-88.
  6. Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada. Analysis of data from the National Notifiable Diseases Reporting System. Ottawa: Public Health Agency of Canada, 2007.
  7. Leland DS. Parainfluenza and mumps viruses. In: Murray PR, Baron EJ, Jorgensen JH et al., eds. Manual of clinical microbiology. 9th ed. Washington DC: ASM Press, 2007.
  8. Robertson S. Mumps. In: Heymann DL, ed. Control of communicable diseases manual. 18th ed. Washington DC: American Public Health Association, 2004;376-79.
  9. American Academy of Pediatrics. Mumps. In: Pickering LK, ed. Red Book: 2003 Report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village: American Academy of Pediatrics, 2003:439-43.
  10. Zimmerman L, Reef S, Wharton M. Mumps. In: Wharton M, Hughes H, Reilly M, eds. Manual for the surveillance of vaccine-preventable diseases. 3rd ed. Atlanta: Centers for Disease Control and Prevention, 2002:7-1–7-12.
  11. Centers for Disease Control and Prevention. Mumps. In: Atkinson W, Hamborsky J, McIntyre L et al., eds. Epidemiology and prevention of vaccine-preventable diseases. 10th ed. Washington DC: Public Health Foundation, 2007;149-58.
  12. Seward et al. Updated Recommendations for the Duration of Isolation Precautions for Persons with Mumps. MMWR 2008; 57:1103-5.
  13. Nova Scotia Health Promotion and Protection. Mumps outbreak case management and surveillance guidelines, May 2007. Version: May 14, 2007. Nova Scotia Health Promotion and Protection, 2007.
  14. Iowa Department of Public Health. Mumps. Revision 5/5/2006. Iowa Department of Public Health, 2006.
  15. Centers for Disease Control and Prevention. CDC health update – corrected: multi-state mumps outbreak. Health Alert Network, April 26, 2006.
  16. National Advisory Committee on Immunization. Statement on mumps vaccine. CCDR 2007;33(ACS-8):1-10.
  17. Iowa Department of Public Health. Public health bulletin: Mass gathering policy – mumps. Iowa Department of Public Health, 18 April, 2006.
  18. Wharton M, Cochi SI, Hutcheson RH et al. Mumps transmission in hospitals. Arch Intern Med 1990;150:47-9.
  19. Kaplan KM, Marder DC, Cochi SL et al. Mumps in the workplace: further evidence of the changing epidemiology of a childhood vaccinepreventable disease. JAMA 1988;260:1434-38.
  20. Gupta RK, Best J, MacMahon E. Mumps and the UK epidemic 2005. BMJ 2005;330:1132-35.
  21. Davidkin I, Jokinen S, Paananen A et al. Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella. J Infect Dis 2005;191:719-23.
  22. Centers for Disease Control and Prevention. Prevention and control of mumps in healthcare settings. http://www.cdc.gov/mumps/prev-control-settings/index.html. Date of access: October 31, 2007.
  23. Public Health Agency of Canada. Prevention and control of occupational infections in health care. CCDR 2002;28(S1):1-276.
  24. Public Health Agency of Canada. Guidelines for reporting a case of infectious tuberculosis on an aircraft (draft). Ottawa: Public Health Agency of Canada, 2007.
  25. Centers for Disease Control and Prevention. Exposure to mumps during air travel – United States, April 2006. MMWR 2006;55(14):401-02.
  26. World Health Organization. Tuberculosis and air travel: guidelines for prevention and control. 2nd ed. World Health Organization, 2006.
  27. International Air Transport Association. Emergency response plan: a template for air carriers – public health emergency. International Air Transport Association, 2005.
  28. Quarantine Act, RSC 2005, c20, s82. Repeals RSC 1985, cQ-I.
  29. Rubin S, Mauldin J, Chumakov K et al. Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains. Vaccine 2006;24:2662-68.
  30. Nöjd J, Tecle T, Samuelsson A et al. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. Vaccine 2001;19:1727-31.
  31. Örvell C, Alsheikhly AR, Kalantari M et al. Characterization of genotype-specific epitopes of the HN protein of mumps virus. J Gen Virol 1997;78:3187-93.
  32. Jin L, Rima B, Brown D et al. Proposal for genetic characterisation of wild-type mumps strains: preliminary standardisation of the nomenclature. Arch Virol 2005;150:1903–09.
  33. Plotkin S. Mumps vaccine. In: Plotkin S, Orenstein W & Offit P, eds. Vaccines. 4th ed. WB Saunders Company, 2003;441-60.
  34. Cohen C, White JM, Savage EJ et al. Vaccine effectiveness estimated, 2004-2005 mumps outbreak, England. Emerg Infect Dis 2007;13(1):12-17.
  35. Gay N, Miller, Hesketh L et al. Mumps surveillance in England and Wales supports introduction of two-dose vaccination schedule. Commun Dis Rep Rev 1997;7:R21-6.
  36. Harling R, White J, Ramsay M et al. The effectiveness of the mumps component of the MMR vaccine: a case-control study. Vaccine 2005;23:4070-74.
  37. Wharton M, Cochi S, Hutcheson R et al. A large outbreak of mumps in the postvaccine era. J Infect Dis 1988;158(6):1253-60.
  38. Vandermeulen C, Roelants M, Vermoere M et al. Outbreak of mumps in a vaccinated child population: a question of vaccine failure? Vaccine 2004;22:2713-16.
  39. Hersh B, Fine P, Kent W et al. Mumps outbreak in a highly vaccinated population. J Pediatr 1991;119:187-93.
  40. Briss P, Fehrs L, Parker R et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 1994;169:77-82.
  41. Peltola H, Heinonen O, Valle M et al. The elimination of indigenous measles, mumps and rubella from Finland by a 12 year, two-dose vaccination program. N Engl J Med 1994;331:1397-402.
  42. Pebody R, Gay N, Hesketh L et al. Immunogenicity of second dose measles-mumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine 2002;20:1134–40.
  43. Davidkin I, Malle M, Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination: a nine-year follow-up. Vaccine 1995;13(16):1617-22.
  44. Park DW, Nam MH, Kim JY et al. Mumps outbreak in a highly vaccinated school population: assessment of secondary vaccine failure using IgG avidity measurements. Vaccine 2007;25(24):4665-70.
  45. Health Protection Agency. MMR vaccination: Priorities for use in mumps outbreak. <www.hpa.org.uk/infections/topics_az/mumps/images/MMRpriorities.pdf>. Date of access: September 18, 2007.
  46. Health Canada and the Public Health Agency of Canada. Strategic risk communications framework and handbook. Thorne Butte: Decision Partners Inc. 2006.
  47. World Health Organization. Outbreak communication: best practices for communicating with the public during an outbreak. World Health Organization, 2005.

Page details

Date modified: